Pralatrexate given orphan drug status for CTCL in Europe

Folotyn.jpg

Reuters and other outlets are reporting that Allos Therapeutics' lead lymphoma drug has been given orphan drug status by the European Commission for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL).

The drug, pralatrexate (brand name: Folotyn) is currently undergoing early-phase trials in CTCL patients, and Allos was previously given orphan drug status for pralatrexate for patients with peripheral T-cell lymphoma (PTCL).

In September 2009, Folotyn became the first drug approved by the FDA for the treatment of PTCL.

By Ross Bonander

Source: Reuters

LymphomaInfo Social